Diabetes > Trials > Design the new Dario

Be 1 of 24 people to help design the new Dario

LabStyle Innovations Corp advances the way consumers engage, monitor, and lead healthier lives through the commercialization of innovative, self-diagnostic technologies and platforms.

The company’s first brand, Dario, is the next generation in diabetes monitoring that connects the user, caregiver, and healthcare professional, anywhere in the world.

Dario represents a new, personalized approach that leverages advances in mobile technology and user-centered diagnostics.

Integrating a glucose meter, lancet, strip dispenser, and innovative application for iOS and Android, Dario’s all-in-one, stylish, compact device, provides immediate feedback, meaningful data, and actionable decisions that can lead to a healthier and better lifestyle.

LabStyle Innovations Corp are inviting 24 people to take a part in designing Dario, if you are a Smartphone user, please join us for a 2-hour session on October 23, 2013.

To take part:

To be eligible to part, you must:

  • Be aged between 19 and 40 years old
  • Use a smart phone
  • Be diagnosed with type 1 or type 2 diabetes
  • Test your blood glucose levels at least 4 times a day
  • Use an insulin pen to inject insulin
  • Be available to attend a 2 hour session - either 10-12am, 12:30-2:30pm or 3-5pm at King's Fund, 11-13 Cavendish Square, London W1G 0AA on October 23, 2013.

There is compensation for travel expenses. In addition, there will be an optional camera interview at the end of session for those who will agree to it.

This has closed.

Who is funding and organising this study? This study is being funded by the Diabetes Vaccine Development Centre (DVDC) in collaboration with the Juvenile Diabetes Research Foundation International (JDRFI). It is being organised by Cardiff University and King’s College London. Who has reviewed this study? The study has been reviewed by the Research Committees of the JDRF and DVDC, and approved by an NHS research ethics committee and the government’s Medicine and Healthcare Products Regulatory Authority (MHRA).